JUNE 2018 RIGHTS ISSUE: INVESTOR PRESENTATION LOrchide nursing - PowerPoint PPT Presentation

JUNE 2018 RIGHTS ISSUE: INVESTOR PRESENTATION L’Orchidée nursing & care home – Ittre (BE)

Warning Investing in the New Shares, the Scrips or trading in the Priority Allocation Rights involves economic and financial risks, as it is the case for every investment in shares. Prospective investors must consider, when taking their investment decision, that they may lose all or part of their investment. See Section "Risk factors" of the Registration Document and Section 1 “Risk Factors” of the Securities Note for a discussion of the factors that should be carefully considered in connection with an investment in the New Shares, the Scrips and trading in the Priority Allocation Rights. Potential investors must be able to bear the economic risk of investing in the New Shares and must be able to cover a total or partial loss of their investment Potential investors must be aware that the Priority Allocation Rights relating to Ordinary Shares and the Priority Allocation Rights relating to Preferential Shares have a different treatment. The Priority Allocation Rights relating to Ordinary Shares will trade on the regulated market of Euronext Brussels while the Priority Allocation Rights relating to Preferential Shares will not be traded on any stock exchange and may only be transferred over the counter. Not for distribution, directly or indirectly, in the United States or to US persons. 2

Disclaimer This presentation has been prepared by the management of Cofinimmo SA/NV, Belgian public real estate investment company (“ Cofinimmo ” or the “Company”), solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this document and any opinions expressed in relation thereto are subject to change without notice. The presentation comprises written material/slides which provide information on the Company and its subsidiaries. Save where otherwise indicated, the Company is the source of the content of this Presentation. Notwithstanding the fact that care has been taken to ensure that the facts stated in this Presentation are accurate, and that the opinions expressed are fair and reasonable, the Company gives no representation or warranty, express or implied, relating to the fairness, accuracy, reasonableness or completeness of the information contained in this Presentation. The Securities Note (including the documents incorporated by reference therein), the Registration Document (including the documents incorporated by reference therein) and the Summary constitute the Prospectus. The English version of the Securities Note and of the Summary were approved by the FSMA on 19 June 2018, in accordance with Article 23 of the Act of 16 June 2006. The approval of the FSMA does not imply an assessment of the appropriateness or quality of the Offering, nor of the condition of the Company. The prospectus is, subject to the usual limitations, available on the Company’s website. An investment in shares entails significant risks. The investors are encouraged to read the Prospectus and in particular the risk factors set out therein. Any decision to invest in securities in the framework of the offering must be based on all information provided in the Prospectus, and any supplements thereto, as the case may be. This Presentation does not contain all the information that may be important for investors. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Not for distribution, directly or indirectly, in the United States or to US persons. 3

Disclaimer (continued) This Presentation and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the “United States”), Australia, Canada or Japan or any other state or jurisdiction which such release, publication or distribution would be unlawful. This Presentation does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities of Cofinimmo SA have not been and will not be registered under the U.S. Securities Act of 1933 (the “Securities Act”) and may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. No public offering of the securities is being made into the United States. In addition, in the United Kingdom, this Presentation is directed at and for distribution only to Qualified Investors who are (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom this Presentation may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents. No announcement or information regarding the capital increase by Cofinimmo with shares in Cofinimmo may be disseminated to the public in jurisdictions other than Belgium where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of shares in any jurisdiction outside of Belgium where such steps would be required. The issue or sale of shares, and the subscription for or purchase of shares, are subject to special legal or statutory restrictions in certain jurisdictions. Cofinimmo is not liable if these restrictions are not complied with by any person. A prospectus has been published in relation to the offering of the securities referred to in this Presentation. A copy of the prospectus is available from 20 June 2018. Investors may not accept an offer of securities referred to herein, nor acquire such securities, unless on the basis of information contained in the prospectus. This Presentation cannot be used as basis for any investment agreement or decision Not for distribution, directly or indirectly, in the United States or to US persons. 4

Table of contents Use of proceeds ________________________________________________________________________ p. 7 Track-record ___________________________________________________________________________ p. 19 Key financials __________________________________________________________________________ p. 23 Transaction details ______________________________________________________________________ p. 26 2018 Forecast __________________________________________________________________________ p. 32 Appendices ____________________________________________________________________________ p. 35 Not for distribution, directly or indirectly, in the United States or to US persons. 5

Management team Françoise Roels Jean Kotarakos Jean-Pierre Hanin Secretary General and Group Counsel CFO (as from 01.06.2018) CEO & Managing Director (as from 09.05.2018) Not for distribution, directly or indirectly, in the United States or to US persons. 6

USE OF PROCEEDS Torenzicht Medical Office Building – Eemnes (NL)

Acceleration of healthcare investments: financing of updated 2018 pipeline 2018 Pipeline 2018 Updated pipeline: published on 08.02.2018: 358 million EUR 68 million EUR 250 250 Total 2018 investments: Total 2018 investments:  Healthcare: 44 million EUR  Healthcare: 314 million EUR  Offices: 18 million EUR  Offices: 39 million EUR  Property of distribution  Property of distribution networks: 6 million EUR networks: 5 million EUR 200 200 6 150 150 100 100 194 2 13 2 50 50 15 76 2 2 2 2 38 7 4 2 5 16 5 13 9 6 6 0 0 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2018 Q2 2018 Q3 2018 Q4 2018 8 Not for distribution, directly or indirectly, in the United States or to US persons.

Breakdown of 2018 investments (358 million EUR) Investments realised, committed and under due diligence for 2018: 358 million EUR 250 Total 2018 investments:  Realised: 211 million EUR  Committed: 55 million EUR  Under due diligence: 92 million EUR 200 150 100 200 10 50 81 46 11 9 0 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Realised Committed Under due diligence 9 Not for distribution, directly or indirectly, in the United States or to US persons.